Investigate / BSX
Understand BOSTON SCIENTIFIC CORP
Can Boston Scientific keep launching competitive next-generation products across its businesses while competition, pricing pressure and trade uncertainty persist?
Snapshot reviewed 2026-10-02. Source published 2026-08-03. No account needed.
AI-assisted synthesis of selected public filings, checked against the cited excerpts. Not a complete analysis.
This is a research starting point, not a buy/sell recommendation or a current valuation. New developments after these sources are not incorporated automatically.
Your research workspace / BSX
Ask better questions. Keep the evidence.
Explore the available sources for BOSTON SCIENTIFIC CORP, then keep what deserves another look.
01 Investor activity
Who reports owning BSX?
6 tracked reported owners. Disclosures are delayed and may describe different quarters—not live holdings or stated motives.
02 Business evidence
Reported evidence
What does the company do?
Boston Scientific develops, manufactures and markets medical devices that physicians use to diagnose and treat conditions, offering less-invasive alternatives to surgery and other traumatic procedures.
Latticework interpretation
What could support the case?
If continued investment in R&D and acquisitions produces next-generation offerings in core and adjacent markets, the company could sustain its growth strategy.
Latticework interpretation
What could break the case?
If competing products, technologies or low-cost alternatives make Boston Scientific’s devices less competitive or obsolete, net sales could be negatively affected.
03 Questions to investigate
Open saved takeaways →Read the full company brief
1. Understand the business
Boston Scientific develops, manufactures and markets medical devices that physicians use to diagnose and treat conditions, offering less-invasive alternatives to surgery and other traumatic procedures.
Source: Annual filing · business description ↗2. What the reported results show
Latest source: 10-Q, reporting period ended 2026-06-30. Selected reported US-GAAP/USD comparisons. The period and basis of each measure are shown separately; year-to-date cash flow is not a quarterly figure. Missing comparisons are collection gaps, not evidence that a company has no revenue or earnings.
| Measure | Current | Prior year |
|---|---|---|
| Revenue from customer contracts ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. Excludes assessed tax; this concept may exclude other company revenue. | $5,442m | $5,061m |
| Operating income ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. | $1,178m | $819m |
| Operating cash flow ↗Six months (year to date): 2026-01-01–2026-06-30; prior 2025-01-01–2025-06-30Both values reported in the current filing. Operating cash flow is not free cash flow or a standalone solvency assessment; inspect the full statement. | $1,822m | $1,827m |
3. The investment debate
Latticework interpretation of the reported results—not the stated motives of any investor.
What could support the case
If continued investment in R&D and acquisitions produces next-generation offerings in core and adjacent markets, the company could sustain its growth strategy.
Supporting filing ↗The strongest caution
If competing products, technologies or low-cost alternatives make Boston Scientific’s devices less competitive or obsolete, net sales could be negatively affected.
Caution evidence ↗An interesting business is not necessarily an attractive investment at today's price. Price, dilution, financing terms and a valuation range still need investigation.
Inspect the evidence behind both sides ↗4. Three questions worth investigating
Use these to guide your research, not as conclusions that have already been proved.
Which new products are driving recent sales growth?
Starting evidence: Management attributes the recent increase in reported net sales to innovation and commercial execution in specific business units.
Investigate next: Review the business-unit net sales discussion to see how concentrated growth is and which products drive it.
Read the supporting filing ↗How exposed is the business to trade policy changes?
Starting evidence: Management says uncertainty around tariffs and trade restrictions could adversely affect operations, distribution costs and results, with uncertain extent and duration.
Investigate next: Examine the Macroeconomic Environment section and risk factors for the described mitigation steps and cost exposure.
Read the supporting filing ↗How much pricing and share pressure appears in the businesses?
Starting evidence: The company discloses it may experience declines in market size, average selling prices, procedure volumes or market share.
Investigate next: Look for business-level commentary on pricing, volumes and competitive pressure in the full filing.
Read the supporting filing ↗5. Decide what to do next
Worth another look? Save this company and return to the evidence. Writing a private view is optional. You do not need to decide whether to invest today.
Save is on this device. Recording a private view requires sign-in and an explicit save. Neither action subscribes you to email or automatically evaluates your thesis.